

All cancer sites




Time-to-first radiotherapy treatment



Australia

New South Wales

Victoria



Canada

Newfoundland and Labrador

Alberta

*Prince Edward Island

Nova Scotia


*New Brunswick

British Columbia

Manitoba

Saskatchewan

Ontario



Norway

Norway




UK

Northern Ireland


England

Scotland

Wales



Time-to-first radiotherapy treatment (days)



Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis. Those not included in the meta-analysis are marked with an asterisk ().

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Oesophageal cancer


Time-to-first radiotherapy treatment



Australia

New South Wales

Victoria



Canada

Alberta


Saskatchewan

British Columbia

Ontario

Nova Scotia

Manitoba



Norway

Norway




UK

England


Scotland

Northern Ireland

Wales



Time-to-first radiotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Stomach cancer


Time-to-first radiotherapy treatment



Australia

New South Wales

Victoria



Canada

Newfoundland and Labrador

British Columbia

Alberta

Saskatchewan

Nova Scotia

Ontario


Manitoba

New Brunswick



Norway

Norway




UK

Northern Ireland


England

Scotland

Wales



Time-to-first radiotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.
Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Rectal cancer


Time-to-first radiotherapy treatment



Australia

New South Wales

Victoria



Canada

Alberta

Prince Edward Island

Newfoundland and Labrador

Saskatchewan


Ontario

Nova Scotia

New Brunswick

British Columbia

Manitoba



Norway

Norway





UK

Northern Ireland

England

Scotland

Wales



Time-to-first radiotherapy treatment (days)

'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.

Lung cancer

Time-to-first radiotherapy treatment



Australia

New South Wales

Victoria



Canada

Newfoundland and Labrador

Alberta

Prince Edward Island

Nova Scotia

British Columbia

Manitoba

New Brunswick

Saskatchewan

Ontario



Norway

Norway






UK

Northern Ireland


England

Wales

Scotland



Time-to-first radiotherapy treatment (days)



'Average time-to-first treatment' relates to the average (median) across all jurisdictions included in the meta-analysis.

Time-to-first treatment refers to the treatment with that specific modality. Treatment can begin before a formal diagnosis; the parameters used in this study are 31 days before diagnosis to 365 days after diagnosis.